See page three Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
H.R. 436/ S. 17 Protect Medical Innovation Act of 2011
H.R. 488 Save Our Medical Devices Act of 2011
H.R. 755 Investing in Our Future Act of 2011
H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011
H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act
H.R. 3203 Novel Device Regulatory Relief Act of 2011
H.R. 3204 Guidance Accountability and Transparency Act of 2011
H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011
H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011
H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 
H.R. 3208 Patients Come First Act of 2011
H.R. 3209 Premarket Predictability Act of 2011
H.R. 3211 Humanitarian Device Reform Act of 2011
H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011
H.R. 3230 Keeping America Competitive through Harmonization Act of 2011
H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011
H.R. 5651, the Food and Drug Administration Reform Act of 2012
HR 6446, Improving Diagnostic Innovations Act of 2012 
S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011
S. 1700 The Medical Device Regulatory Improvement Act 
S. 1865 The Patient Access to Medical Innovation Act 
S. 1943 Novel Device Regulatory Relief Act of 2011 
S. 1995 Medical Device Patient Safety Act 
S. 3187, the Food and Drug Administration Safety and Innovation Act See page 7 Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
H.R. 436/ S. 17 Protect Medical Innovation Act of 2011
H.R. 488 Save Our Medical Devices Act of 2011
H.R. 755 Investing in Our Future Act of 2011
H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011
H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act
H.R. 3203 Novel Device Regulatory Relief Act of 2011
H.R. 3204 Guidance Accountability and Transparency Act of 2011
H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011
H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011
H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 
H.R. 3208 Patients Come First Act of 2011
H.R. 3209 Premarket Predictability Act of 2011
H.R. 3211 Humanitarian Device Reform Act of 2011
H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011
H.R. 3230 Keeping America Competitive through Harmonization Act of 2011
H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011
H.R. 5651, the Food and Drug Administration Reform Act of 2012
HR 6446, Improving Diagnostic Innovations Act of 2012 
S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011
S. 1700 The Medical Device Regulatory Improvement Act 
S. 1865 The Patient Access to Medical Innovation Act 
S. 1943 Novel Device Regulatory Relief Act of 2011 
S. 1995 Medical Device Patient Safety Act 
S. 3187, the Food and Drug Administration Safety and Innovation Act See page five Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
H.R. 436/ S. 17 Protect Medical Innovation Act of 2011
H.R. 488 Save Our Medical Devices Act of 2011
H.R. 755 Investing in Our Future Act of 2011
H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011
H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act
H.R. 3203 Novel Device Regulatory Relief Act of 2011
H.R. 3204 Guidance Accountability and Transparency Act of 2011
H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011
H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011
H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 
H.R. 3208 Patients Come First Act of 2011
H.R. 3209 Premarket Predictability Act of 2011
H.R. 3211 Humanitarian Device Reform Act of 2011
H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011
H.R. 3230 Keeping America Competitive through Harmonization Act of 2011
H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011
H.R. 5651, the Food and Drug Administration Reform Act of 2012
HR 6446, Improving Diagnostic Innovations Act of 2012 
S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011
S. 1700 The Medical Device Regulatory Improvement Act 
S. 1865 The Patient Access to Medical Innovation Act 
S. 1943 Novel Device Regulatory Relief Act of 2011 
S. 1995 Medical Device Patient Safety Act 
S. 3187, the Food and Drug Administration Safety and Innovation Act
HCR - Health Issues MMM - Medicare/Medicaid MED - Medical/Disease Research/Clinical Labs
132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE 132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE 132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE
CEPHEID
2200 Pennsylvania Ave NW, Suite 800 W, Washington, DC, DC, 20037, US
MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS